Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors
Status:
Recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single-arm, Phase II investigator-initiated trial of precise
thymalfasin-regulated therapy combined with hypofractionated radiotherapy, PD-1/PD-L1
inhibitor sequential GM-CSF for treatment of advanced refractory solid tumors.